Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.36 |
| ▸ | PPARA | Q07869 | 7/20 | 0.36 |
| ▸ | PPARD | Q03181 | 5/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034475 | 0.93 | DGAT1 (0.40) | DGAT1PPARAPPARGL3MBTL1 | |
| SCHEMBL6035708 | 0.91 | PPARA (0.43) | DGAT1PPARAPPARDPPARG | |
| SCHEMBL6035774 | 0.91 | AURKA (0.35) | PPARAPPARDPPARGMAPK1L3MBTL1 | |
| SCHEMBL6035144 | 0.90 | PPARG (0.35) | PPARAPPARDPPARGMAPK1L3MBTL1 | |
| SCHEMBL6034583 | 0.88 | SMN1; SMN2 (0.39) | DGAT1PPARAPPARDPPARGMAPK1 | |
| SCHEMBL6034648 | 0.87 | DGAT1 (0.35) | DGAT1PPARAPPARDPPARGMAPK1 | |
| SCHEMBL6034824 | 0.85 | PPARG (0.34) | DGAT1TRPA1PPARAPPARDPPARG | |
| SCHEMBL6034478 | 0.83 | PPARA (0.41) | DGAT1PPARAPPARDPPARGL3MBTL1 | |
| SCHEMBL6035564 | 0.82 | PLA2G4B (0.42) | DGAT1PPARAPPARDPPARG | |
| SCHEMBL1634400 | 0.82 | PPARA (0.40) | PPARAPPARDPPARGMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PTGS2 4593/4885DGAT1 1683/4885TRPA1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.